Latest News on cancer and Covid-19 testing

Improving Patient Education and Access: How Can We Better Leverage Advances in Cancer Diagnostics and Treatment

Over the last several decades, scientific research has revealed that cancer is a disease primarily caused by mutations found in genes. Further studies have helped identify which key mutations develop into potentially deadly cancers. That information has helped researchers in the pharmaceutical industry to develop specially tailored therapies designed to target those mutations. These targeted […]

Read More


Frontline Pembrolizumab Combo Approved by FDA for NSCLC

Pembrolizumab (Keytruda) has been granted an accelerated approval by the FDA for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell lung cancer (NSCLC), regardless of PD-L1 expression. The approval was based on part 2 of cohort G in the KEYNOTE-021 trial, in which the […]

Read More

genotoxic stress

A novel p53-Cdc7 link induced by genotoxic stress

An insightful commentary by Professor Masai based at the Department of Genome Medicine, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan about Oncologica’s recent publication relating to how  p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress. Read more here

Read More

Every child with cancer to have tumour DNA sequenced to find best treatment

Every child with a tumour in Britain will have their cancer DNA sequenced so they can get the best possible drugs and help the UK catch up with treatment in Europe and the US. The charity Children with Cancer UK has today announced £1.5 million in funding so that from today youngsters can be screened […]

Read More

Mesothelioma shows promising response to existing immunotherapy drug

An existing immunotherapy drug called pembrolizumab appears to be effective in the treatment of malignant pleural mesothelioma, a rare and aggressive lung cancer that is primarily caused by exposure to asbestos. Writing in The Lancet Oncology, researchers describe the first study to show a positive result from using the antibody drug against this rare cancer. […]

Read More


PAT KENNY SHOW talk available as podcast

Dublin 27 March 2017 PAT KENNY SHOW Ireland feature Oncofocus “a Revolutionary test can tailor the best therapy for cancer patients” GUESTS: Dr David Fennelly Oncologist at St Vincent’s Hospital and Blackrock clinic DUBLIN Prof Gareth H Williams Oncologica Ltd Medical Director

Read More

revolutionary new test

Oncofocus a revolutionary test that can tailor the best therapy for cancer patients

A revolutionary new test, which takes the “guesswork” out of deciding what treatment will be most effective for a cancer patient, has been launched in Ireland. Dr David Fennelly, oncologist at St Vincent’s Hospital in Dublin, said the Oncofocus test has great potential to improve the survival of cancer patients. This will include not just […]

Read More

Oncologica live on The Pat Kenny Show – IRELAND

Oncologica will be guest on The Pat Kenny Show – IRELAND Monday 27th March 2017, 9:30- 10:30am

Read More

Binimetinib Improves PFS in NRAS-mutant Melanoma

Binimetinib significantly prolonged progression-free survival compared with dacarbazine and was associated with a manageable safety profile among patients with advanced, NRAS-mutant melanoma, according to a study published in The Lancet Oncology.1 For the ongoing, international, open-label, phase 3 NEMO trial ( Identifier: NCT01763164), researchers evaluated the efficacy and safety of binimetinib, a MEK inhibitor, compared […]

Read More

New Insights Into Rucaparib Activity in Ovarian Cancer

The PARP inhibitor rucaparib slowed progression of relapsed BRCA-mutant ovarian cancer regardless of whether the mutations were somatic or germline, a new analysis of a phase II trial showed. Patients with germline or somatic BRCA mutations had a median progression-free survival (PFS) of about 13 months when treated with rucaparib. Additionally, patients with BRCA1 or […]

Read More


NICE says yes to Novartis’ Afinitor in kidney cancer

Novartis’ Afinitor (everolimus) has received backing from UK cost-effectiveness body NICE for routine use in patients with advanced kidney cancer. The drug is now available as a second-line treatment in cases of advanced renal cell carcinoma that has progressed during or following treatment with vascular endothelial growth factor (VEGF)-targeted therapy. The decision follows a positive […]

Read More

Efficacy of Osimertinib in Advanced T790M-positive NSCLC

Osimertinib confers a high overall response rate and encouraging progression-free survival among patients with T790M-positive, advanced non-small cell lung cancer (NSCLC) who progress after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment, according to a study published in the Journal of Clinical Oncology.1 The phase 2 extension component of the multicenter, open-label, phase […]

Read More